[ORGANIZATION]
Novartis AG
Featured in 3 tracked stories · first seen
Situations
Alteogen Hybrozyme technology licensing and commercial sales
3 clusters · 5 sources · last updated
Latest: Alteogen signs up to $3.2B licensing deal with Novartis
South Korean biotechnology firm Alteogen has expanded its Hybrozyme platform through significant licensing agreements. In August 2026, the company secured an exclusive licensing deal valued at up to $365 million with a g
CAR T-cell therapy market and research developments
3 clusters · 4 sources · last updated
Latest: CARsgen Therapeutics announces 2026 interim results
The global CAR T-cell therapy market is projected to experience significant growth through the end of the decade. Early projections estimated the market would reach approximately $13.56 billion by 2031, driven by rising